| Size | Price | Stock | Qty |
|---|---|---|---|
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
| Targets |
2-Hydroxyphenylboronic acid does not have a specific primary biological target, as it functions primarily as a chemical reagent and synthetic intermediate rather than a direct pharmacological agent. However, the compound's boronic acid group can form reversible covalent bonds with diols and other nucleophilic groups in biological molecules, enabling interactions with sugars, glycoproteins, and enzymes. The hydroxyl group can participate in hydrogen bonding with biological targets. Boronic acids are known to inhibit serine proteases and other enzymes through covalent modification of active site residues. The compound may serve as a precursor for the synthesis of enzyme inhibitors, particularly those targeting proteases and glycosidases. Its ability to form reversible covalent bonds with diols makes it valuable for the development of sensors and targeted drug delivery systems.
|
|---|---|
| ln Vitro |
2-Hydroxyphenylboronic acid is employed as an intermediary in pharmaceuticals.
In vitro, 2-hydroxyphenylboronic acid is used as a building block in organic synthesis for the construction of more complex molecules. The compound's boronic acid group allows for Suzuki-Miyaura cross-coupling reactions with aryl halides to form biaryl compounds. The hydroxyl group provides additional functionality for further derivatization through etherification, esterification, and other transformations. The compound is a useful research chemical that serves as a building block in organic synthesis. In medicinal chemistry, it serves as a scaffold for the synthesis of boronic acid-containing drug candidates, particularly protease inhibitors and other enzyme inhibitors. Its ability to form reversible covalent bonds with diols makes it valuable for the development of sensors for glucose and other sugars. In materials science, it is used in the synthesis of boronate ester-containing polymers and materials. |
| Enzyme Assay |
Cell-free assays for 2-hydroxyphenylboronic acid are focused on its use as a chemical reagent. Standard protocols for Suzuki-Miyaura coupling involve mixing the compound with an aryl halide, a palladium catalyst, a base, and an appropriate solvent at elevated temperatures under an inert atmosphere. The reaction progress is monitored by TLC or HPLC, and the products are purified by column chromatography. The compound's ability to form boronate esters with diols can be studied using various analytical techniques including NMR spectroscopy and mass spectrometry. Its use as a building block for pharmaceutical synthesis involves standard organic synthesis procedures.
|
| Cell Assay |
Cellular assays are not commonly performed with 2-hydroxyphenylboronic acid itself, as it is primarily a chemical intermediate rather than a bioactive compound. However, its derivatives may be evaluated in cell-based systems for various biological activities. Boronic acid derivatives are tested in cancer cell lines for antiproliferative activity, in enzyme assays for inhibitory activity, and in sensor applications for glucose detection. The parent compound itself is not used as a test article in cell-based experiments due to its primary role as a synthetic building block. Instead, it is used in the synthesis of drug candidates that are subsequently tested in cellular assays.
|
| Animal Protocol |
Animal studies are not conducted with the parent compound 2-hydroxyphenylboronic acid. Its derivatives may be evaluated in animal models for therapeutic efficacy, but the parent compound itself is not administered to animals. Boronic acid derivatives are known to have various pharmacological activities, and derivatives of this compound may be tested in animal models of cancer, diabetes, or infectious diseases. The parent compound itself is not used in animal studies due to its role as a synthetic intermediate.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 2-hydroxyphenylboronic acid are not available, as the compound is primarily a chemical reagent rather than a drug candidate. With a molecular weight of 137.93 g/mol and a melting point of 178-182 °C, the compound would be expected to have moderate polarity and limited membrane permeability if administered. However, comprehensive pharmacokinetic studies including absorption, distribution, metabolism, and excretion have not been performed, as the compound is not intended for therapeutic use. For research purposes, the compound is typically handled as a neat chemical and not administered to living organisms for pharmacokinetic profiling.
|
| Additional Infomation |
2-Hydroxyphenylboronic acid is a research chemical, not an approved drug. It has no clinical trial or marketing approval status for therapeutic use. The compound combines the aromaticity of the benzene ring with the special properties of boric acid in its structure. It is a useful research chemical that serves as a building block in organic synthesis. The compound has a molecular formula of C6H7BO3 and a molecular weight of 137.93 g/mol. It has a melting point of 178-182 °C and a boiling point of 327.3 °C. It contains varying amounts of anhydride and should be stored at room temperature in a cool and dark place, preferably below 15 °C.
|
| Molecular Formula |
C6H7BO3
|
|---|---|
| Molecular Weight |
137.93
|
| Exact Mass |
138.048
|
| CAS # |
89466-08-0
|
| PubChem CID |
2773454
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
327.3±44.0 °C at 760 mmHg
|
| Melting Point |
178-182°C
|
| Flash Point |
151.7±28.4 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.582
|
| LogP |
0.85
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
107
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OB(C1C(O)=CC=CC=1)O
|
| InChi Key |
YDMRDHQUQIVWBE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H7BO3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8-10H
|
| Chemical Name |
(2-hydroxyphenyl)boronic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.2501 mL | 36.2503 mL | 72.5005 mL | |
| 5 mM | 1.4500 mL | 7.2501 mL | 14.5001 mL | |
| 10 mM | 0.7250 mL | 3.6250 mL | 7.2501 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
